Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2017 - 11 - 01
点击次数: 0
Positions: Head of Research and Development
Company: I-Mab Biopharma Co., Ltd
个人简介:
Joan obtained PhD in life science and license as a physician with board certification in US. She also had 3 postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. She practiced as a psychiatrist and worked in Eli Lilly & Co, Wyeth and Pfizer, where she was responsible for global clinical development programs cross phase 1-4. She has extensive experiences working with FDA, EMEA, CFDA, PMDA, KFDA and etc. She holds an academic position as the adjunctive professor in Indiana University School of Medicine.Joan was sent to China by Pfizer in 2011 as the China clinical head and joined Hengrui as the CMO in May 2013. She was granted the honor of “Talent of Innovation” by the “National Thousand Talent Program”. In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. She is also elected as the executive committee member of China New Drug Research Evaluation Committee. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China development head in 2015 and responsible for all the development programs, where she led multiple successful NDA approvals by CFDA. During this time, she is elected as the co-chair of RDPAC R&D core team. Most recently Joan I-Mab biopharma as the head of R&D and is leading the efforts of China to China and China to global.
发布时间: 2017 - 11 - 01
点击次数: 0
Positions: CEO
Company: Beijing Mabworks Biotech Co.Ltd
个人简介:
Dr. Feng Li is currently CEO of Beijing Mab-Works, Inc., a biotech company focusing on therapeutic antibody development. Before joining Mab-Works in late 2011, Feng has worked inUSbioPharm industry for over 10 years. He was a Principle Engineer, Manager of Pilot Plant and Cell Culture Development at Genentech, Inc., a Senior Scientist at Amgen, Inc., and a Process Engineer at Tanox, Inc. Feng received his Ph.D. degree in Chemical Engineering from Rice University.
发布时间: 2017 - 11 - 01
点击次数: 0
Positions: Partner
Company: Qiming Venture
个人简介:
Dr. Min Wang Irwin joined Qiming Venture Partners as venture partner. Dr. Irwin has brought more than 20 years’ experience in RD, partnering, market access and organization development in global and China. She has established several big medical and development teams including product development, medical affairs, regulatory affairs, project management as well worked closely with company commercial teams for product lunch and life cycle management. In addition, she worked extensively with BD to complete several product licensing deals. Under her leadership, teams had successfully received NDA approval for close to 20 drugs in small molecules, biological products, medical devices and consumer healthcare products across many therapeutic areas in China and Canada.Most recently Dr. Irwin worked at Takeda as VP, site head of Takeda Development Center Asia. She also worked in GlaxoSmithKline’s R&D Center in Shanghai where she served as Vice President China Medicine Development since January 2013. Prior to joining GSK, she was with Bayer Healthcare for 13 years in China and Canada. Dr. Irwin’s career also includes Clinical Science and Research with Parke-Davis and biotech startup company, Dimethaid Pharmaceutical.Dr. Irwin has a Ph.D. in Diabetes Research from University of Toronto, a Master of Science degree in Anti-Infection after Burn Injury and a Doctor of Medicine, both from Third PLA Medical University in China.
发布时间: 2017 - 11 - 01
点击次数: 0
Positions: Board Member, Senior VP & CMO
Company: Betta Pharmaceuticals Co, Ltd
个人简介:
Fenlai Tan, M.D., Ph.D., is the Senior VP and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd. He holds a Ph.D. degree in medical physiology from University of Arkansas for Medical Sciences, and then completed his post-doctoral fellowship at Cleveland Clinic.Dr. Fenlai Tan has been actively involved in drug development for decades and is especially experienced in clinical study design and implementation for small molecule anti-cancer targeted drugs. He joined Betta Pharmaceuticals in 2007 where he successfully led the phase I, II, III and IV clinical trials of icotinib (an EGFR tyrosine kinase inhibitor) for the treatment of advanced NSCLC harboring EGFR mutation. In 2011, icotinib (Conmana), as the first home-grown anti-cancer targeted drug, was approved by CFDA and launched in China. A comment titled “Icotinib: kick-starting the Chinese anti-cancer drug industry” was published together with the clinical data of the icotinib phase III study (ICOGEN) on the prestigious medical journal, Lancet Oncology. In addition, Dr. Tan oversees the clinical development (phase I-III clinical studies) of many other innovative drugs at Betta in the field of oncology, diabetes, dermatology, ophthalmology, etc. He and his team have conducted more than 30 clinical studies during the past ten years.Dr. Fenlai Tan is a clinician and a leading biomedical scientist who has authored more than 40 scientific publications and secured more than 20 patents. In 2014, he was awarded as a Distinguished Expert of China Federation of Returned Overseas Chinese. In 2013, he was selected as a member of the national “Recruitment Program of Global Experts”. Dr. Fenlai Tan currently is member of ASCO, AACR, ESMO, IASLC and ADA.